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LAPAROSCOPIC STAGING IN CARCINOMA STOMACH AND ITS IMPACT ON TREATMENT PLAN
INTRODUCTION Gastric cancer ranks fifth among cancers in men and seventh among cancers in
women in India. Geographic variation in distribution of gastric cancers is a known fact and is
observed both worldwide and in India. Gastric cancer is a major problem in North-eastern and
Southern states of India as seen in data from National Cancer Registry. According to the National
Cancer Registry, age-adjusted incidence rate of stomach cancer in males was highest in Chennai
(11.1 per 100,000) compared to 1.6 per 100,000 in Bhopal. There have been studies on the data
collected by cancer registry on malignancies of affecting...
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ABSTRACT 
TITLE OF THE STUDY “Laparoscopic staging in carcinoma stomach and its impact on treatment 
plan” 
DEPARTMENT   : Department of General surgery Unit III 
NAME OF THE CANDIDATE : Dr. Ashish Sam Samuel  
DEGREE AND SUBJECT : M S General Surgery 
NAME OF THE GUIDE  : Dr. Inian Samarasam 
OBJECTIVE 
Primary Objectives:  
To study the efficacy of staging laparoscopy as compared to Computerized Tomography in assessing- 
metastatic disease (peritoneal and liver surface), T3 and T4 disease and location of primary tumor. 
To study the role of staging laparoscopy in altering the management plan. 
Secondary Objective: 
To look at the role of peritoneal cytology  
METHODS 
This is a prospective study done among 66 consecutive patients diagnosed with 
adenocarcinoma stomach. Findings of both investigations were compared with final 
histopathology report. Peritoneal fluid aspiration cytology was done in all patients.  
RESULTS 
Of the 66 patients staging laparoscopy (SL) detected 23 patients with peritoneal metastases as 
against none by computed tomography (CT). SL detected 10 patients with ascites and 5 with 
liver surface metastases as against 6 patients with ascites and none with liver metastases by CT. 
There was a change in plan in 30 patients out of 66 patients recruited for the study (46%) based 
SL findings. T- Stage on staging laparoscopy shows fair agreement with gold (k=0.34, p=0.0004) 
so also the site of tumor was in agreement. Peritoneal fluid was positive in 7.58% by using the 
routine Papanicolaou staining. 
KEY WORDS: Staging Laparoscopy, Peritoneal fluid Cytology, Computed tomography, Peritoneal 
disease-P1,P2,P3 , T3 and T4 disease, Liver Surface metastsis 
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INTRODUCTION 
Gastric cancer ranks fifth among cancers in men and seventh among cancers in women in India. 
Geographic variation in distribution of gastric cancers is a known fact and is observed both 
worldwide and in India. Gastric cancer is a major problem in North-eastern and Southern states 
of India as seen in data from National Cancer Registry.(1) According to the National Cancer 
Registry, age-adjusted incidence rate of stomach cancer in males was highest in Chennai (11.1 
per 100,000) compared to 1.6 per 100,000 in Bhopal.(1) (2) 
There have been studies on the data collected by cancer registry on malignancies of affecting 
gastrointestinal tract. These have shown that the incidence of gastric cancer is on the decline, 
this more marked in Delhi. (2) 
Stomach cancer ails from the fact that late presentation of symptoms brings patient to a doctor 
at advanced stages of the disease. The population-based survival studies have shown that 
despite improved treatment options, gastric cancer remains to have poor prognosis. This 
highlights the fact that appropriate investigative modalities for more accurate staging of the 
disease may contribute to better survival rates. Surgical resection remains the mainstay of 
treatment.(3)(4) Neoadjuvant, adjuvant, palliative chemotherapy form part of the 
multimodality treatment of this disease.(5)   
It needs to be stressed that optimum therapy can be offered only when tumor spread is 
accurately evaluated. The assortment of newer and sophisticated investigative modalities 
available presently like endoscopic and trans abdominal ultrasound, CT scan, MRI, PET-CT etc; 
have failed in accurately detecting peritoneal and occult surface liver metastases. Small volume 
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peritoneal involvement, occult liver metastases and lymph nodal involvement are still being 
detected only during surgery.(6) This has necessitated the need for an investigative modality 
that will pick peritoneal disease, disease involving liver surface and under surface of diaphragm. 
Laparoscopy stands out in its ability to look at these areas specifically.(7) Staging laparoscopy 
will hence possibly help in planning optimum treatment option. This study is designed to 
evaluate the role of diagnostic laparoscopy in staging of gastric cancer and to look at the 
change in treatment plan.  
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RELEVANCE OF THE STUDY 
 
Carcinoma of stomach is one of the important causes of cancer related deaths in India. Newly 
detected stomach cancers in India in year 2001 were 24985 among men and 11890 among 
women.(1) Mean annual age-standardized (world population) incidence of gastric cancer per       
100,000 residents in India in 1990 was 9.7 for men and 4.7 for women.(1) Gastric carcinoma is 
often detected in its late stages in India. Surgical resection is the only potential curative 
treatment available. However, surgical resection is dependent on the staging of the disease. 
 Currently, Computerized Tomography (CT) is used as a routine preoperative tool for staging the 
disease. But CT Scan most often under-stages the disease as it does not totally exclude liver and 
peritoneal metastasis. Hence many patients undergo unnecessary laparotomy. Vistre et al., in 
1988, reported that 25% of patients with gastric cancer underwent unnecessary laparotomy, 
and 13% to 23% developed complications due to the laparotomy.(8) This fact underlines the 
requirement of a better diagnostic tool, which can pick up advanced disease and avoid 
unnecessary laparotomy in already morbid individuals.  Laparoscopic visualisation of the 
intraperitoneal organs will give a better staging of the disease extent and the metastatic 
involvement of the peritoneum and liver surface.(7) Various studies done show that 
laparoscopy is more sensitive than Computerized Tomography in detecting small volume 
peritoneal disease and liver surface involvement.(9) Other modalities like endoscopic 
ultrasound though effective in detecting early gastric cancers their sensitivity in detecting 
peritoneal disease is low.(10)(11)  It is important that patients with incurable disease are not 
subject to radical surgery. 
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General Surgery unit III of CMC Vellore deals with upper GI surgeries and is high volume centre 
for gastrectomies. In year 2010-2011 the total number of inpatient admissions was 1059 of 
which 28% were of Upper GI specialty including gastric cancers. Of the total gastric surgeries 
done in 2010-2011, 138 were for carcinoma stomach. The patients who present to this centre 
come from varied geographical locations in India and therefore the results of the study may be 
applicable to any part of our country.  
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AIMS AND OBJECTIVES 
 
 
AIM: 
 
To determine the role of staging laparoscopy in the staging of operable gastric adenocarcinoma 
and its impact on treatment plan 
 
OBJECTIVES: 
Primary Objectives:  
o To study the efficacy of staging laparoscopy as compared to Computerized Tomography in 
assessing  
1. metastatic disease (peritoneal and liver surface) 
2. T3 and T4 disease 
3. Location of primary tumor 
o To study the role of staging laparoscopy in altering the management plan. 
Secondary Objectives: 
1. To look at the role of peritoneal cytology  
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REVIEW OF LITERATURE 
 
ANATOMY 
The stomach is the most proximal abdominal organ of the digestive tract connecting the 
abdominal esophagus and the first part of duodenum. 
EXTERNAL FEATURES 
The stomach has two surfaces: anterior and posterior, two curvatures: greater and lesser and 
two orifices- cardia and pylorus. 
The cardiac orifice is attached to the lower end of esophagus. It lies behind left 7th costal 
cartilage at the level of vertebra T11. Just proximal to the cardia at the gastro esophageal 
junction, there is a physiological sphincter, which controls reflux of acid into the duodenum. 
The pyloric orifice connects the stomach to the proximal duodenum. It lies half inch to the right 
of the median plane at the level of lower border of vertebra L1 in an empty stomach and in the 
supine position. Its position is indicated on the surface of stomach by a circular groove 
produced by the underlying pyloric sphincter and by the pre-pyloric vein which lies in front of 
the constriction. 
The greater curvature is convex forming the left border of the stomach. It gives attachment to 
greater omentum, the gastrosplenic ligament and gastrophrenic ligament. It presents a cardiac 
notch at its upper end which separates it from the esophagus.(12) 
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The lesser curvature is concave forming the right border of the stomach. It gives attachment to 
the lesser omentum. Angular notch or incisura angularis marks the most dependant part of the 
curvature. 
The anterior surface faces forwards and upwards and the posterior surface faces backwards 
and downwards. 
LANDMARKS 
Topographically, the stomach is divided into regions: the cardia and gastro-esophageal junction, 
the fundus, the body or corpus, the antrum, and the pylorus. 
The fundus is the superior most part of the stomach. The angle of His is where the fundus 
meets left side of the GE junction. 
 The body of the stomach is the largest region. The inferior extent of the fundus is considered to 
be the horizontal plane of the GE junction, where the body starts. 
The antrum begins at the incisura angularis where the lesser curvature turns abruptly to the 
right. It comprises distal 25 to 30% of the stomach. 
The fundus and corpus harbor acid-secreting glands, whereas the antrum harbors alkaline-
secreting surface epithelium and endocrine, Gastrin secreting G-cells. 
On endoscopy, the GE junction is distinguished by the transition between the flat, pale, 
stratified epithelium of the esophagus and the lush, pink, glandular epithelium of the upper 
stomach. The junction between the acid-secreting corpus and the non-acid secreting antrum is 
also distinguished by the rugal pattern. Those of the antrum are linear and aligned with the 
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long axis of the organ, whereas those of the corpus are convoluted and oriented obliquely. The 
pylorus is visualized, outlined by the underlying ring of muscularis.(12)  
 
RELATIONS 
PERITONEAL RELATIONS 
Both the surfaces of stomach are lined by peritoneum. Layers of the peritoneum meet at the 
lesser curvature and become continuous with the lesser omentum. The two layers meet along 
the greater curvature to form the greater omentum. The two layers meet to form the gastro-
splenic ligament near the cardiac end of the greater curvature. On the posterior surface near 
the cardiac end the peritoneum is reflected on to the diaphragm as the gastro-phrenic 
ligament. Above this ligament a small part of the posterior surface of stomach is in direct 
contact with the left crus of diaphragm and is called the bare area of the stomach. 
 
VISCERAL RELATIONS 
Liver, diaphragm and the anterior abdominal wall forms the anterior relations of the stomach. 
Posterior surface is related to structures which form the stomach bed such as the diaphragm, 
left kidney, left suprarenal gland, pancreas, transverse mesocolon, splenic flexure of the colon 
and the splenic artery. 
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BLOOD SUPPLY 
ARTERIAL SUPPLY 
The stomach is supplied by 1) the left gastric artery, a branch of the celiac axis, which supplies 
the cranial portion of the lesser curvature.  2) The right gastric artery, a branch of the common 
hepatic artery, which supplies the caudal portion of the lesser curvature. 3) The right 
gastroepiploic artery, a branch of the gastroduodenal artery, which supplies the antrum and 
lower body. 4) The left gastroepiploic artery, a branch of the splenic artery, which supplies the 
upper body and (5) a series of short gastric arteries, which are branches of splenic artery  
supply the fundus and cranial portion of the body. 
 
VENOUS SUPPLY 
Right and left gastric, right and left gastroepiploic and short gastric veins of the stomach drain 
into the portal vein directly or via the superior mesenteric vein or splenic vein. 
NERVE SUPPLY 
Extrinsic sympathetic nerve supply is derived from segments T5 to T10 via the splanchnic nerves 
to celiac ganglion. Post ganglionic sympathetic nerves then travel from celiac ganglion to 
stomach along the blood vessels. 
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Extrinsic parasympathetic nerve supply is derived from the vagus nerves which forms the 
esophageal plexus. This esophageal plexus above the hiatus forms the left anterior and right 
posterior vagal trunks. Anterior vagus sends branches to the liver in gastro hepatic ligament and 
travels along the lesser curvature as the anterior nerve of Latarjet. It gives branches to the body 
of stomach and terminates near the incisura angularis as the crow’s foot and give branches to 
antropyloric region. Posterior vagus send branches to the celiac plexus and continues along the 
posterior lesser curvature. The branch that the posterior vagus sends to the posterior fundus is 
called as the criminal nerve of Grassi. 
Neurons in the myentric and sub mucosal plexuses form the intrinsic nervous system of the 
stomach. 
 
LYMPHATIC DRAINAGE 
Lymphatics of the stomach run in close proximity to blood vessels. The cardia and medial half of 
the body drain into nodes along the left gastric and celiac axis. The proximal greater curvature 
of the stomach drains into nodes along the left gastro-epiploic or splenic hilum. Greater 
curvature half of the distal stomach drains into nodes along the right gastro-epiploic hilum. The 
lesser curvature side of the antrum drains to the right gastric and pyloric nodes. The nodes 
along both the greater and lesser curvature commonly drain into the celiac nodes. There is a 
rich anastomosis of lymphatics that drain the stomach.  
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Figure 1: Lymph node stations in gastric carcinoma 
(1) Right cardiac (2) left cardiac (3) lesser curve (4) greater curve (5) supra-pyloric (6) Sub pyloric 
(7) left gastric artery (8) common hepatic artery (9) coeliac artery (10) splenic hilum (11) splenic 
artery (12) hepatoduodenal 
 
Sixteen lymph nodal stations have been identified according to the Japanese Research Society 
for the study of Gastric Cancer (JRSGC) for the purposes of staging of gastric carcinoma.(13) 
 
 
Stations of nodal spread in gastric cancer according to the system of the Japanese 
Research Society of study of Gastric Cancer along with their designations as local (R1), regional 
(R2) or distal-regional (R3) spread 
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STATION LOCATION ANTRUM BODY/FUNDUS 
1 RIGHT CARDIA R2 R1 
2 LEFT CARDIA R2 R1 
3 LESSER CURVE R1 R2 
4 GREATER CURVE R1 R2 
5 SUPRAPYLORIC R.GASTRIC 
A. 
R1 R2 
6 INFRAPYLORIC R1 R2 
7 L.GASTRIC A. R1 R1 
8 COMMON HEPATIC A. R2 R2 
9 CELIAC AXIS R3 R3 
10 SPLENIC HILUM R3 R1 
11 SPLENIC A. R3 R1 
12 HEPAODUODENAL LIG. R2 R1 
13 PANCREATIC HEAD R2 R2 
14 ROOT OF SMA R3 R3 
15 MIDDLE COLIC A. R3 R3 
16 PARA AORTIC R3 R3 
Table1: Lymph node stations in gastric carcinoma(13)  
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RISK FACTORS FOR CARCINOMA STOMACH 
 
Infections Helicobacter pylori 
 Epstein bar virus 
Diet High salt intake 
 Nitrites and nitrates 
 Low intake of fruits and vegetables 
Pernicious anemia  
Habits  Smoking  
 Alcohol consumption 
Gastric surgeries Stump carcinoma 
Peptic ulcer disease  
Ionizing radiation  
Hereditary factors Blood group A 
 Gastric polyps 
 Hereditary diffuse gastric cancer  
 Hypertrophic gastropathy 
Table 2: Risk factors for carcinoma stomach(14) 
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CLINICAL FEATURES OF GASTRIC CANCER 
The symptoms of stomach cancer tend to be vague and nonspecific hence eluding early 
detection. This can be attributed to the fact that both the organ in question and the cavity that 
contains it are accommodative to distention. Gastric cancer share early symptoms with benign 
disease.  This prevents the patient and the treating doctor to be more cautious of the 
symptoms. Outside of Japan, screening for gastric cancer is not performed. . Even in 
industrialized countries like The United States Of America, it is quite common for patients to be 
misdiagnosed with disease of benign etiology and to have undergone treatment for the same 
before realizing the folly. 
According to Paul F. et al the most common symptoms and there frequency of occurrence is as 
follows: 
SYMPTOM FREQUENCY 
Abdominal pain 50 to 60% 
Weight loss  40% 
Overt upper gastrointestinal bleed 16 to 17 % 
Table 3: Symptoms in gastric cancer and their frequency of occurrence(15) 
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The same investigators have analyzed over one thousand cases of stomach cancer at M. D. 
Anderson Centre and have found that many of the symptoms are site specific. Dysphagia was 
seen more commonly in proximal tumors while distal tumors had vomiting and nausea as 
prominent symptoms. Patients with linitis plastica most commonly presented with early 
satiety.(15) 
Physical examination may reveal the stigmata of the disease but most often these are 
indication of progression of the disease. Jaundice, palpable intra abdominal mass, free fluid, left 
supra clavicular lymphadenopathy, umbilical nodule, Blummer shelf nodules are indications of 
advanced disease.  
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DIAGNOSIS 
Carcinoma stomach is one of the commonest reasons for oncological death in our country. 
Early detection and treatment of the same is paramount. Gastric cancer remains to have only 
surgery as the potentially curative treatment. Therefore the disease needs to be adequately 
staged for optimum treatment. In patients who are suspected with carcinoma stomach 
investigations are directed towards - Diagnosis and Staging of the disease.   
Diagnosis is usually using endoscopy and biopsy. Patients who present with symptoms 
suspicious of carcinoma stomach undergo upper gastrointestinal endoscopy and biopsy from 
the lesion. 
Various staging options are available.  Endoscopic ultrasonography and multidetetector 
computed tomography are presently in vogue.  
UPPER GASTRO INTESTINAL ENDOSCOPY AS A DIAGNOSTIC TOOL IN CARCINOMA STOMACH 
Upper gastrointestinal endoscopy is the diagnostic tool most commonly employed in gastric 
malignancies.  British consensus guidelines recommends that the gastric cancer is diagnosed by 
seeing the lesion on endoscopy and confirming diagnosis by histo pathological examination of 
minimum six tissue biopsy from the lesion. If there the biopsy results of suspected lesion are 
inconclusive then a repeat biopsy is warranted.(16)(17)  
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Of late there has been a surge of technological innovations in the field of gastrointestinal 
endoscopy. This has helped in detecting more number of early gastric cancers. Chromo 
endoscopy using indigo dye spraying helps in identifying early gastric cancer.  Magnifying 
endoscopy with narrow-band imaging (NBI) helps in visualizing micro vascular observation of 
the micro vascular architecture of the mucosa and micro surface pattern of the tumor. Endo 
cytoscopy helps in visualizing the cell itself and even the nuclei.(18)(19) All these have helped in 
identifying early gastric cancer but the crux of the matter is late presentation of the disease in 
our country.  Majority of the time the disease is beyond the scope of endoscopic therapeutic 
interventions. Easy availability, the simplicity of the procedure, the possibility to biopsy the 
lesion and the cost effectiveness of the procedure entail it to remain as the first port of call in 
the diagnosis of carcinoma stomach.(16) 
ENDOSCOPIC ULTRSONOGRAPHY AS A STAGING MODALITY IN CARCINOMA STOMACH 
Gastric carcinoma appears hypoechoic on endoscopic ultrasound. This modality has its 
importance in the fact the early gastric cancers are now being treated by endoscopic mucosal 
resection. However the purview of this modality does not extend beyond T1 and T2 disease. 
Endoscopic ultrasound may underestimate the depth of invasion by the tumor and 
overestimate lymph nodal involvement due to inflammatory process around the nodes. 
However distant nodal metastases are difficult to be detected on endoscopic ultrasound. 
(11)(20)  
 
19 
 
 
COMPUTED TOMOGRAPHY IN STAGING OF CARCINOMA STOMACH  
The most commonly performed and widely available one is computerized tomography. The 
overall accuracy of transverse CT and volumetric CT for tumor staging is 77% and 84% 
respectively.(21) It has been noted that extraserosal involvement and metastases are difficult 
to be precisely detected on CT.  The tumor staging of disease, especially T3 and T4 is a 
challenge as it is hard to distinguish fat stranding around the tumor as due to infiltration or 
inflammation. Peritoneal carcinomatosis is another condition which the computerized 
tomography does not detect when in small volumes.  
In a review done by R.Hargunani et al, detection and staging of gastric neoplasia using multi 
detector computed tomography and endoscopic ultra sound was studied. MDCT aids the 
detection and radiological staging of gastric carcinoma when it is combined with multi planar 
reconstruction the accuracy of T stage determination improves to 89 per cent as compared with 
axial images alone which is 73 per cent.(22) However endoscopic ultrasound has a better 
diagnostic rate of 74 to 94 per cent in determination of T stage.(22) But EUS is more invasive 
and distant nodal disease and metastases are difficult to be picked up .It has its own advantage 
of being useful in the therapeutic management of early gastric cancer (when the lesions are 
confined to mucosa and sub mucosa endoscopic mucosal resection is a possibility). Nodal 
staging in gastric cancer is a challenge whatever the technique used. Enlarged nodes detected 
by either EUS or CT may subsequently be proven to be inflammatory; on the contrary normal 
sized nodes may be metastatic. EUS can potentially detect metastases in liver, mediastinum and 
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even peritoneum. However, it is not primarily employed for detection of distant disease. CT 
remains the initial method of choice.   
 
In a similar study by Chiao-Yun Chen, the accuracy for peritoneal involvement was 96 per cent 
using multi detector computed tomography. This study did not look at the accuracy of 
transverse CT in detecting peritoneal disease. 
In a study of 63 patients using MDCT and EUS by Suryaprakash Bhandari, et al; the accuracy of 
lymph node staging was 75 per cent for MDCT and 79 per cent for EUS.(23) D'Ugo DM, et al 
found that the sensitivity of computerized tomography for T3 and T4 disease was 23.2% and 
48.3%, respectively. 21 out the 100 patients who underwent laparoscopy had metastasis which 
not detected on preoperative staging CT.(24) 
Gonzale-Moreno S et al studied the effectiveness of computed tomography in the detection of 
peritoneal carcinomatosis. Even with improvements in technology and availability of contrast-
enhanced, multi detector computed tomography, the early detection and characterization of 
peritoneal disease is a major challenge. Often small volume peritoneal implants remain 
undetected. Even so contrast-enhanced, multi detector computed tomography is the mainstay 
in detection of peritoneal disease.(25) 
Sung Wook Hwang et al In 277 patients with gastric cancer endoscopic ultrasound and 
computed tomography were done as part of operative evaluation. Results of pre operative 
endoscopic ultrasound and MDCT were compared to post operative histopathological findings. 
The overall accuracy of EUS and MDCT for T stage was 74.7 per cent and 76.9 per cent 
respectively. Similarly the overall accuracy for N stage was 66 per cent and 62.8 per cent 
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respectively. However this study did not look to the aspect of peritoneal and liver surface 
metastases.(26) 
Therefore there is need for better diagnostic tool for peritoneal disease.  According to National 
Comprehensive Cancer Network (NCCN) guidelines 2011, following protocol is followed. 
 
Tis/T1a, medically unfit Endoscopic mucosal resection(EMR) and 
endoscopic surveillance 
Tis/T1a, medically fit EMR or Surgery 
Potentially resectable, medically fit , M0 Surgery or Preoperative chemotherapy 
followed by surgery 
Potentially resectable, medically fit , M1 Palliative therapy 
Unresectable tumors, medically fit, M0 Chemoradiation(definitive) 
Unresectable tumors, medically fit, M0 Palliative therapy 
Medically unfit M0  Chemoradiation(definitive) 
Medically unfit M1 Palliative therapy 
Table 4: NCCN guidelines for treatment in carcinoma stomach 
Hence according to NCCN guidelines laparoscopy can be considered in resectable or 
unresectable M0 disease.(27) 
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ROLE OF POSITRON EMISSION TOMOGRAPHY 
This modality uses difference in metabolic activity between normal tissues and tumor tissues in 
identifying the disease. Positron emission tomography uses the property of increased glycolytic 
activity of the tumor tissues and they metabolize fluoro-2-D-glucose at higher rate than normal 
tissues. The results with PET are a mixed bag. There are studies which have quoted sensitivity of 
93% in detecting the primary lesion in gastric carcinoma. However it is found that in 
approximately 20% of patients with gastric cancer, the primary tumor is not detected by PET. 
The reason for the above phenomenon is due to the fact that poorly differentiated and 
mucinous carcinomas are not PET avid. It is also found that nodal assessment by this modality is 
poor.(25) 
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ROLE OF LAPAROSCOPIC STAGING IN CARCINOMA STOMACH 
Laparoscopic staging is the use of a fiber optic laparoscope to determine the extent of 
involvement by a malignant tumor within the peritoneal cavity. 
HISTORICAL PERSPECTIVE 
Laparoscopy was first described by the beginning of 20th century.  Interestingly it was first 
promoted as an adjunct in diagnosing diseases in the abdomen. It gained foothold as a 
therapeutic tool among general surgeons only by 1986 when it was used for laparoscopic 
cholecystectomy .Newman of Glasgow modified the Edison’s electric bulb so that it could b 
mounted on a cystoscope. Georg Kelling is credited with performing a laparoscopic surgery in 
dogs. In human it was first attempted by Jacobaeus of Sweden. Benedict of Boston used 
laparoscopy in diagnosis of liver disease, ascites, cancers of stomach and colon. It was Waugh 
from Mayo Clinic who first reported that laparoscopy was the best tool to assess ascites and the 
accuracy rate with which laparoscopy diagnosed intraabdominal malignancy was 93%.(28) 
COMPLICATIONS OF LAPAROSCOPY 
Laparoscopy is a fairly safe procedure. The complications encountered can be divided as 
following: 
1. Complications related to access 
2. Complications of pneumoperitoneum 
3. Complications of surgical procedure per se 
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ACCESS RELATED COMPLICATIONS 
Jansen et al found that 57% of complications in gynecological cases were related to insertion of 
trocar. Problems associated with access account for 0.3% complications and they include major 
injuries to retroperitoneal vessels and to the bowel.(29) A study conducted by Mayol et al 
showed that there was 5% complications related with access(29) and they included –  
1. Abdominal wall hematoma (2%) 
2. Umbilical hernia (1.5%) 
3. Umbilical wound infection (1.2%) 
4. Penetrating injuries (0.2%) 
However the rate of complications related to access can be reduced by using open technique of 
entry. 
PNEUMOPERITONEUM RELATED COMPLICATIONS 
Study conducted by Patel et al found the patients undergoing laparoscopic cholecystectomy 
were at high risk of developing deep vein thrombosis. The pneumoperitoneum decreases 
cardiac output by up to 30% and mean arterial pressure increases in 16% of cases.(29) However 
the duration of pneumoperitoneum in staging laparoscopy is less and the ill effects of 
pneumoperitoneum on the cardiovascular system can be ameliorated by preloading with 
isotonic fluid and by keeping the patient in supine position as much as possible. However, due 
to the short duration of the procedure, such problems due to pneumoperitoneum are very rare.  
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COMPLICATIONS OF SURGICAL PROCEDURE PER SE 
Since there is no major handling of viscera involved in staging procedure, visceral injuries are 
quite far and in between.  The major complications occurring are the off camera injuries. These 
are minimized with experience of the surgeon. 
 
NEED FOR LAPAROSOPIC STAGING 
There have been many prospective and retrospective studies in this regard. D Mahadevan et al 
conducted a prospective study involving 40 patients from 2006 to 2008 to assess the value of 
preoperative laparoscopic staging for gastric cancer. Histopathological examination was 
considered gold standard for the staging. This was compared with CT and laparoscopy. Most 
significant finding of the study was that laparoscopy detected 7 cases of peritoneal metastases 
which were not picked on CT. Hence these patients were saved the morbidity and mortality 
associated with unnecessary laparotomy. In this study assessment of T factor was quite variable 
.While T3, T4 disease could be easily assessed, lesions less than T3 were difficult to be assessed 
laparoscopically. Sensitivity of laparoscopy for T3 tumors were 90.3 per cent as against 58 per 
cent for CT. Hence this study concluded that laparoscopy is sensitive in detecting peritoneal 
metastases and helped in avoiding unwanted laparotomy.(8) 
Andronik Kapiev et al conducted a retrospective study on 361 gastric cancer patients. All 
patients in this study underwent a CT preoperatively. Patients with T4 disease or un-resectable 
disease were excluded from the study. Diagnostic laparoscopy was performed on these 
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patients. They found that 23 of 28 patients had peritoneal spread undetected on CT. They 
concluded that diagnostic laparoscopy has to be considered in all stomach cancer patients who 
will be undergoing curative resections.(30) 
Between January 2006 and December 2008 a prospective study was conducted by Valentin 
Muntean et al. They looked at laparoscopy and laparoscopic ultrasonography in accurate 
staging of alimentary tract cancers. In their study unnecessary laparotomies were avoided 36.4 
per cent of patients. These patients did not have distant metastases on pre operative staging 
imaging. The overall morbidity for staging laparoscopy was 2.45 per cent and they had no 
mortality. In this study they also looked the value of laparoscopic ultrasound and peritoneal 
cytology.  This study included esophageal, gastric, hepatobiliary, pancreatic and colorectal 
malignancies. They concluded that staging laparoscopy can avoid unnecessary laparotomies in 
all these malignancies and aid in faster recovery and earlier time to adjuvant treatment in 
which laparotomy was avoided.(31) 
Gian Carlo Roviaro et al studied 83 patients from 1994 to 1999 with gastric cancer. 71 of 83 
patients underwent laparoscopic staging. All of these patients had preoperative staging with 
computed tomography. In their series laparoscopy accuracy for T3 lesion reached 88.5% and T4 
81.2%.  In 6 out 71 patients laparoscopy revealed causes for unresectable tumors and hence 
avoided unnecessary laparotomy.(32) 
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IS STAGING LAPAROSCOPY REUIRED FOR ALL PATIENTS WITH CARCINOMA STOMACH? 
Staging laparoscopy is useful in the detection of peritoneal disease and the likelihood of 
peritoneal spread is very small when there are T1 or T2 lesions.  There is evidence to say that 
staging laparoscopy not necessary in early disease.  
Staging laparoscopy is recommended in following scenarios 
1. Whenever Neoadjuvant treatment is planned upfront. 
2. In T3 and T4 disease (the likelihood of peritoneal disease in T1 and T2 disease is very low). .  
3. Laparoscopic staging provides opportunity to obtain peritoneal fluid for cytology.  
 
 Lehnert et al studied 120 patients with adenocarcinoma of stomach of which 96 patients had 
laparotomy upfront with curative intent in 81 and palliative intent in 15 patients. In two of the 
patients out of 81 planned for curative resection laparotomy was abandoned due to peritoneal 
metastases. Fifteen patients underwent laparoscopic staging primarily. Peritoneal metastasis 
was observed in six patients and the other four did not have peritoneal involvement. He 
concluded that diagnostic laparoscopy is not warranted for all cases of adenocarcinoma of 
stomach.(33) 
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PERITONEAL FLUID CYTOLOGY 
Peritoneal fluid cytology is helpful in prognosticating gastric carcinoma. The impact of 
peritoneal cytology is evident in the fact that it has been included in the present AJCC staging as 
M1 disease. Therefore it is used as an adjutant in staging of gastric cancer. Several studies have 
shown that there is reduced survival when cytology is positive. Presence of malignant cells in 
peritoneal lavage has been reported in the range of 6.8 to 23 percent.  James J. Mezhir et al 
conducted a prospective trial to ascertain the value of diagnostic peritoneal lavage in detecting 
positive peritoneal fluid. They found that 12 patients of the 22 had positive cytology which was 
4.5 per cent.(34) In a review done by Martin R et al, it has been noted that the likelihood of 
finding tumor cells in a cytology specimen appears to be related to the tumor stage of the 
disease. The review further notes that when the cytology uses Papanicolau method there is no 
patients with T1 and T2 disease who have positive cytology. The cytology positivity rate was 10 
percent in T3 and T4 disease and 59 percent in M1 disease. However the sensitivity increases if 
immunohistochemistry or reverse transcriptase polymerase chain reaction is used.(16) If we 
look in detail into these studies one will find that cytology can be positive even in T1 or T2 
disease especially when immunohistochemistry or reverse transcriptase reaction technique is 
employed. In a study conducted by Martin J.K Jr et al, abdominal fluid cytology in 76 patients 
with various gastro intestinal malignant lesions was looked into. 43 per cent of patients with 
gastric cancer were found to have positive tumor cells in their peritoneal washings. They found 
tumor cells in early malignancies.(16) 
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Based on the current TNM 7 recommendations, where peritoneal disease is staged as M1 
disease, it is essential to look at the cytology in the pre operative staging of gastric cancer.  
 
 
 
 
PAPANICOLAU STAIN IN PERITONEAL FLUID CYTOLOGY 
 
Figure 2: Papanicolau stain in peritoneal fluid cytology 
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STAGING OF GASRIC ADENOCARCINOMA ACCORDING TO UICC/AJCC STAGING (7TH EDITION) 
PRIMARY TUMOR T  
TX PRIMARY TUMOR CANNOT BE ASSESSED 
T0 NO EVIDENCE OFPRIMARY TUMOR 
Tis CARCINOMA INSITU 
T1 TUMOR INVADES LAMINA PROPRIA /MUSCULARIS 
MUCOSAE/SUBMUCOSA 
T1a TUMOR INVADES LAMINA PROPRIA /MUSCULARIS 
MUCOSAE 
T1b INVADES SUBMUCOSA 
T2 INVADES MUSCULARIS PROPIA 
T3 PENETRATES SUBSEROSAL CONNECTIVE TISSUE WITHOUT 
INVASION 
T4 INVADES SEROSA - 
T4a VISCERAL PERITONEUM 
T4b ADJACENT STRUCTURES 
REGIONAL LYMPH NODES 
N 
 
NX CANNOT BE ASSESSED 
NO NO REGIONAL NODE METS 
N1 1TO 2 REGIONAL NODES INVOLVED 
N2 3TO6 
N3 7 OR MORE 
N3a 7 TO 15 
N3b 16 OR MORE 
DISTANT METASTASIS M  
MO NO DISTANT METASTASIS 
M1 DISTANT METASTASIS 
Table 5: Staging of gasric adenocarcinoma according to UICC/AJCC staging  
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STAGE O Tis N0 M0 
STAGE 1A T1 NO M0 
STAGE 1B T2 N0 M0 
 T1 N1 M0 
STAGE  IIA T3 N0 M0 
 T2 N1 M0 
 T1 N2 M0 
STAGE IIB T4a N0 MO 
 T3 N1 M0 
 T2 N2 MO 
 T1 N3 MO 
STAGE IIIA T4a N1 M0 
 T3 N1 M0 
 T1 N3 M0 
STAGE IIIB T4b N0 MO 
 T4b N1 MO 
 T4a N2 M0 
 T3 N3 M0 
STAGE IIIC T4b N2 M0 
 T4b N3 M0 
 T4a N3 M0 
STAGE IV ANY T ANY N M1 
Table 6: Stage grouping in carcinoma stomach 
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TREATMENT OPTIONS 
ADJUVANT CHEMORADIOTHERAPY 
MACDONALD’S TRIAL 
Curative surgical resection alone would not be adequate to prevent recurrence in 
adenocarcinoma of the stomach.  Macdonald’s trial in 2001 looked into the effectiveness of 
surgery plus postoperative chemoradiation in adenocarcinoma of stomach. In the surgery-only 
group the median overall survival was 27 months, as compared with 36 months in the surgery 
plus chemoradiotherapy group.  They concluded that adjuvant chemoradiotherapy should be 
instituted in all those who have increased for recurrence of gastric adenocarcinoma.(35)  
 
ARTIST TRIAL  
In this trial chemoradiotherapy was compared with chemotherapy as an adjuvant treatment 
option. 458 patients who had completely resected tumors were included in this study. Patients 
were randomized into two arms one in whom Capcitabine and Cisplatin were given the other 
group received radiotherapy along with afore said chemotherapy regimen. 75.4% patients 
completed treatment in chemotherapy only arm and 81.7% completed treatment in 
chemoradiotherapy arm. The addition of radiation to chemotherapy did not change the disease 
free survival (p=.0862) but chemoradiotherapy arm saw better outcomes with those with node 
positivity which was statistically significant. This significance was maintained in a multivariate 
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analysis. The estimated hazard ratio in this sub group was 0.6865and 95% confidence interval of 
0.4735 to 0.9952. (36) 
 
 
ADJUVANT CHEMOTHERAPY 
S1 TRIAL 
This was Japanese randomized control trial where oral fluoropyrimidine derivative S-1 was used 
as adjuvant chemotherapeutic agent. In 2011 the 5 year follow up report was published. They 
found that in whom gastrectomy with D2 lymphadenectomy was done when Adjuvant agent S-
1 added the overall survival rate increased to 71%as against 61.1% in surgery alone group. They 
also noticed that adding the adjuvant agent S-1 increased the relapse free survival rate at 5 
years to 65.4% as against 53.1% in surgery only group.(37) 
 
CLASSIC TRIAL  
This was an eastern trial looking into the benefits of adjuvant chemotherapy. They studied the 
effects of giving Capcetabine and Oxaliplatin after D2 gastrectomy and surgery alone in 1035 
patients with stage II and III disease. At a median follow-up of 34 months, chemotherapy was 
associated with a significant improvement in three-year disease-free survival, with only a 
borderline statistically significant improvement in overall survival (83% versus 78 %). However, 
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with longer follow-up they could show that there was improvement in overall survival with 
chemotherapy. This was statistically significant (five-year overall survival 78% versus 69 %). (38) 
 
 
NEOADJUVANT CHEMOTHERAPY 
MEDICAL RESEARCH COUNCIL ADJUVANT GASTRIC INFUSIONAL CHEMOTHERAPY (MAGIC) 
TRIAL 
Between 1994 and 2002 a major trial in United Kingdom created a paradigm shift in the way we 
viewed the treatment of gastric cancer. The United Kingdom National Cancer Research Institute 
(NCRI) conducted the Medical Research Council Adjuvant Gastric Infusional Chemotherapy 
(MAGIC) trial which recruited 503 patients over eight years. This was the first randomized trial 
of its kind which conclusively demonstrated a survival benefit by using perioperative 
chemotherapy in those who had resectable adenocarcinoma of the stomach, gastro esophageal 
junction, and lower esophagus, compared with surgery alone. This trial used the ECF regimen 
for perioperative chemotherapy which included Epirubicin, Cisplatin and continuous infusion 5-
fluorouracil. The five year survival rate in the intention-to-treat (ITT) analysis was 36%. The 
study showed that in comparison patients treated with surgery alone had a five year survival 
rate of 23%. This study also showed that there was significant improvement in Progression-free 
survival with perioperative chemotherapy (hazard ratio for progression, 0.66; 95% confidence 
interval, 0.53–0.81; P <.001). This trial has downsides to it. This study was open to recruitment 
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during 1994 to 2002. The downsides to this trial are that t patients did not have detailed 
preoperative staging of the disease. The surgery done was not standardized and chemotherapy 
commencement and completion rates were poor. (39) 
 
 
 
FRENCH MULTICENTER TRIAL (FNLCC/FFCD) 
This trial was conducted to look at the effect of perioperative chemotherapy on overall survival 
in those who have undergone curative resection for gastric and esophageal adenocarcinoma. 
This trial made use of 5- fluorouracil and Cisplatin as chemotherapeutic agents. It was found 
that those who had perioperative chemotherapy had 35 percent reduction in the risk of disease 
recurrence. They also experienced significant reduction in the risk of death (31% reduction). 
 
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER RANDOMIZED TRIAL 
Unlike the above mentioned trials the EORTC trial failed to demonstrate any survival benefit in 
patients undergoing perioperative chemotherapy. In this trial patients with locally advanced 
disease was recruited and they were randomized in to surgery alone and surgery plus 
chemotherapy group. They used Cisplatin and five-fluorouracil as chemotherapeutic agents. 
The group which received perioperative chemotherapy had more post operative complications. 
At median follow up of 4.4 years the patients had no survival advantage.(40) 
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This trial showed a significantly increased R0 resection rate but failed to demonstrate a survival 
benefit. Possible explanations are low statistical power ( the study stopped due to poor 
accrual), a high rate of proximal gastric cancer including  oesophageal adenocarcinomas and/or 
a better outcome than expected after radical surgery alone due to the high quality of surgery 
with extensive lymphadenectomy.(40) 
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SURGERIES FOR GASTRIC CANCER 
Surgery has remained the mainstay of treatment in carcinoma stomach and in essence is the 
only possible curative treatment in this disease. Therefore surgical resection should aim at 
complete removal of all macroscopically visible disease and direct at getting histological disease 
free margins. This result is reached in 45% of gastric cancers studied in population-based series 
and up to 55–60% of cases in high volume centers for gastrectomies. The type of operation 
conducted depends on the site, the T- stage of the disease and the extent of the lymph nodal 
involvement.(13) 
TOTAL GASTRECTOMY 
Total gastrectomy is the removal of whole of the stomach for lesions in the upper and middle 
third of the stomach. Here, the stomach is resected en bloc including the entire greater 
omentum and lesser omentum. Adequate lymph node clearance is done. The gastrointestinal 
continuity is reconstructed by oesophagojejunostomy. 
SUBTOTAL GASTRECTOMY 
This resection is done for distally placed tumors of the stomach where proximal stomach is 
preserved and the rest of the tumor is resected with 5 cm proximal clearance. The 
gastrointestinal continuity is reconstructed by gastrojejunostomy. 
 
PALLIATIVE SURGERY 
In patients who have an advanced obstructing distal tumor or a bleeding tumor, palliative 
surgery is appropriate. Palliative surgery would include palliative gastrectomy which removes 
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the tumor and reconstructs the gastrointestinal tracts. The non surgical method of palliation of 
an obstructing tumor is by endoscopic stenting.  
LYMPHADENECTOMY 
D1 LYMPHADENECTOMY – involves removal of N1 nodes – stations 1 to 7.  
This lymphadenectomy is done when nodes are N0.It is a removal of nodes along with lesser 
curve, greater curve and pylorus. 
D2 LYMPHADENCTOMY involves removal of D2 nodes – D1 + stations 8 to 12. 
This lymphadenectomy is done for N1 stage of the disease. Here nodal stations 1 to 11 are 
removed. (41) 
D3 LYMPHADENCTOMY more distal nodes (stations 13 to 16 are removed).  
This is done when nodal stage is N2.The nodes removed are hepato-duodenal along the middle 
colic artery. Hence nodal stations 1 to 16 are removed.  
R0 RESECTION 
Here a complete resection is done with no microscopic residual tumor. 
R1 RESECTION 
Here a complete resection is done with no macroscopic residual tumor. Yet the margins are 
positive for tumor tissue microscopically. 
R2 RESECTION 
Gross tumor is left behind at the end of resection. This resection at the most is only palliative. 
. 
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MATERIALS AND METHODS 
 
STUDY SETTING: 
Christian Medical College, Vellore is a 2200 bedded, tertiary care, multi-specialty teaching 
hospital in South India.  
STUDY DESIGN 
This is a prospective study done among patients diagnosed with carcinoma stomach in the 
General Surgical Unit III of Christian Medical College and Hospital, Vellore from 1st September 
2011 to 31st October 2013 
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INCLUSION CRITERIA:  
Patients with histologically confirmed adenocarcinoma of stomach planned for surgical 
intervention based on preoperative staging investigations which should include computed 
tomography scan done within 8 weeks before surgery. 
 
EXCLUSION CRITERIA:  
1. Preoperative CT scan demonstrating distant metastasis. 
2. General condition of the patient precluding any surgical intervention. 
3. Previous surgeries precluding Laparoscopy.  
 
 
STUDY DURATION:  
1st September 2011 to 31st October 2013 
APPROVAL: 
This study was reviewed and cleared by the Institutional Review Board (IRB No: 7622) and the 
Ethics Committee of CMC Vellore. 
Funding for the study was provided by the Fluid Research Grant. 
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SAMPLE SIZE CALCULATION 
Statistical method used to arrive at sample size was “Two Proportion – Hypothesis Testing – Large 
Proportion – Equal Allocation” method. The reference study used to arrive at the sample size was the 
one done by D Mahadevan et al, consecutive patients were studied and sensitivity of laparoscopy was 
compared to that of CT scan. Laparoscopy was found to more sensitive than CT in T3, T4 and M1 
disease. (8) 
Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation 
Overall 
Proportion in group I (CT-sensitivity) = 0.575 
Proportion in group II (Laparoscopy-sensitivity) = 0.85 
Risk difference         = -0.275 
Power (%)                        = 80 
Alpha Error (%)                  = 5 
Side                            = 2 
Required sample size for each arm   = 41 
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Alpha Error (%)          Power (%) Sample size 
                                        70                        51 
            1                          80                        62 
                                        90                        78 
                                           70                        33 
            5                          80                        41 
                                        90                        55 
                                           70                        25 
            10                        80                        32 
                                        90                        44 
Table 7: Sample size calculation 
Similarly sample size with alpha error of 5% and power of 80 for M- stage, T2, T3, T4 were 
calculated to be 6, 58, 28 and 22 respectively. Hence for the study a sample size of 70 was 
considered taking into account attrition, dropouts during the study period. 
Finally the results were calculated using Kappa statistics. Kappa coefficient is used as measure 
of inter observer agreement for qualitative items. The interpretation of Kappa values was made 
based on Altman (1991) criteria.(42) 
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Altman (1991) criteria 
Value of K Strength of agreement 
< 0.20 Poor 
0.21 - 0.40 Fair 
0.41 - 0.60 Moderate 
0.61 - 0.80 Good 
0.81 - 1.00 Very good 
Table 8: Altman criteria for kappa statistics(42) 
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METHODS 
Patients with signs and symptoms suggestive of carcinoma stomach underwent endoscopy and lesion 
was biopsied. Those confirmed with adenocarcinoma on histopathology had a staging computed 
tomography. The CT findings were reported according to the   standardized protocol. The time interval 
between the imaging and surgery was not more than 8 weeks.  
A CT protocol has been designed for this study is given below. 
CARCINOMA STOMACH CT PROTOCOL   
PATIENT PREPARATION:   
* 6 Hours fasting  
* Water as contrast medium - 1000ml   
* 400 ml to be administered immediately before examination   
* Patient position:   
Supine –for Gastric cardia or fundus lesion (based on endoscopic findings) 
Prone - for distal to cardia or fundus (based on endoscopic findings) 
CT scan was done using Philips Brilliance 6 slice CT scanner or Seimens Somatom Emotion 16 slice CT 
scanner. Both machines take the scan with 5mm cuts.  Computed tomography was reported by single 
radiologist and recorded according to the following CT abdomen and pelvis reporting format. 
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Staging of disease was according to the criteria published by R. Hargunani et al, which was a 
modification of Ba-Ssalamah et al.  According to this the staging by computed tomography was as 
follows 
T STAGING   
T0- No e/o alteration of gastric wall with preservation of normal fat plane   
T1- Thickened mucosal layer with preserved low density stripe at the base of the lesion   
T2 - Transmural enhancement with focal wall thickening   
     -  Loss of layered structure   
     - Smooth outer border of the thickened gastric wall   
     - Clear fat planes around the lesion   
T3 - Irregular outer border of the thickened gastric wall and / or a blurred fat plane around the lesion   
T4 - Obliteration of fat plane between the gastric lesion and adjacent organs or infiltration of other 
organs   
NODAL STAGING:  Metastatic involvement of the nodes were based on following findings 
Perigastric nodes - > 6mm   
Extraperigastric nodes - > 8 mm  
Round shape, longitudinal-transverse ratio - <1.5  
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Fatty hilum that is eccentric / missing   
Marked heterogeneous enhancement   
 
 
Figure 3: T3 lesion 
 
 
Figure 4: T4 lesion  
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STAGING LAPAROSCOPY 
Those included in the study had a detailed plan of management made with inputs from the 
multidisciplinary team. These patients underwent preoperative evaluation for gastrectomy and pre 
anesthetic check up. Those deemed fit for anesthesia and major resection underwent staging 
laparoscopy under general anesthesia in the same sitting as the main surgery.  Patients were placed in 
in supine position preoperative antibiotics were given at the time of induction. Nasogastric tube placed 
and urinary catheter was inserted under antibiotic cover. For the laparoscopy one 10mm supraumblical 
and two 5mm ports was used. Once the pneumoperitoneum is created with insufflation of carbon 
dioxide a 30 degree laparoscope was used to visualize the intraperitoneal contents. A suction device 
was introduced through one of the 5mm ports and ascitic fluid was suctioned for cytology.
 
Assessment 
of the following will be done using the laparoscope: 
     Mobility of the tumor,  
Location of the primary lesion  
Metastatic tumor deposits in the following areas were looked at: 
1. Diaphragm 
2. oesophageal hiatus 
3. Upper and lower surfaces of both lobes of liver 
4. Lesser and greater omenta  
5. Stomach surface 
6. Pelvic peritoneum 
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7. Lesser sac ( lesser sac was entered only if there was no evidence of tumor deposits 
anteriorly ) 
Lesions on the peritoneum and liver surface were not routinely biopsied. Only when there was a 
doubt regarding the metastatic disease, a frozen section was performed.  Metastatic lesions were 
classified into P1, P2, P3 and an on-table decision was made regarding the resection of the tumor. 
This was according to the flow chart given below: 
DIAGNOSTIC LAPAROSCOPY
PERITONEAL DISEASE
P1                              P2                          P3
BULKY T4
PALLIATIVE
SURGERY                NEOADJUANT        CHEMO
 
Figure 5: Peritonea disease treatment protocol 
P1, P2, P3 are defined according to the recommendations of Japanese Research Society for Gastric 
Cancer. 
 
 
49 
 
P1 lesion: few metastases in adjacent peritoneum(9) 
 
Figure 6: P1 lesion 
 
 
P2 lesion: Few metastases to distant peritoneum(9) 
 
Figure 7: P2 lesion 
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P3 lesion: numerous metastases in distant peritoneum(9) 
 
Figure 8: P3 lesion 
If deemed necessary to confirm the diagnosis of metastasis biopsies were taken from the lesions. 
 
The definition of variables T and M was according to the 7th edition of UICC Guidelines for staging of 
carcinoma stomach. 
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PERITONEAL FLUID FOR CYTOLOGY 
Ascitic fluid was collected at the time of laparoscopy using suction device. Ascitic fluid was sent for 
cytology on the same day in specially provided 50ml bottle containing anticoagulant. The fluid was 
transferred into a Cytospin (Shandon) which centrifuges at 800rpm for 5 minutes. The slides made were 
treated with Cornoy’s fixative for 5 minutes or in case of heavily blood stained slide for 15 minutes. The 
slide was treated with Isopropanol 95% and stained with Pap stain. All slides will be looked at and 
reported by the cytologist. 
Clinical research form was used in entering all clinical data and relevant operative and post operative 
data. Histopathological staging of the disease was also entered. 
Histopathology 
Surgical specimen sent for histopathological examination was initially identified by the name and 
hospital number. Each specimen was given a barcode. Specimen was then sent for grossing. Gross 
study of the specimen was done by a pathologist. The specimen was then cut and placed in white or 
green colored cassettes. This was then treated with 10% formalin. Cassettes were then placed in an 
automatic processor (Lieca). The specimen passes through 70, 80, 90, 95% of alcohol and three 
containers of absolute alcohol and through three containers of toluene and finally through two buckets 
of paraffin. After 12 hours in the processor and embedding, the blocks were cut using a rotatory 
microtome which would yield 3 microns to 5 micron size specimen which was then stained with routine 
Haematoxylin and Eosin stains and study under microscope. 
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RESULTS 
DEMOGRAPHICS 
SEX DISTRIBUTION  
 
Figure 9: Sex distribution  
There was male preponderance in our study with 65% of study population being males. 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
N
PERCENTAGE
43 
65% 
23 
35% 
FEMALE
MALE
53 
 
 
AGE DISTRIBUTION 
VARIABLE MINIMUM MAXIMUM MEAN 
AGE 19 77 53 
 
Table 9: Age distribution 
Patients in their fifth decade were common in our study.  Youngest patient was 19 years and 
oldest 77 years of age 
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TYPE OF HISTOLOGY 
 
Figure 10: Type of histology 
 
Poorly differentiated adenocarcinoma constituted the majority of histological types in this 
study population making up 70%.  
 
 
 
 
  
2 
14 
39 
WELL DIFFERENTIATED
ADENOCARCINOMA
MODERATELY
DIFFERENTIATED
POORLY DIFFERENTIATED
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PERITONEAL DISEASE DETECTED 
PERITONEAL DISEASE ON COMPUTED TOMOGRAPHY Vs STAGING LAPAROSCOPY 
 
Figure 11: Peritoneal disease on CT Vs laparoscopy 
CT – computed tomography 
P1, P2, P3 – peritoneal metastases as described by Japanese classification 
Of the 66 patients included in the study computed tomography did not pick up any peritoneal 
disease while staging laparoscopy detected 23 patients with peritoneal metastases. Of the 23 
peritoneal metastases majority was P2 disease. 
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PERITONEAL DISEASE SPECIFIC TREATMENT DONE 
 
 
Figure 12: Peritoneal disease specific treatment instituted 
All 5 patients with P1 disease, the laparoscopy was continued with a palliative gastric resection.  
Seven out 13 patients with P2 disease underwent palliative resection and in 4 patients with P2 
disease, resection was abandoned and they underwent palliative chemotherapy. All seven 
patients who had P3 disease underwent palliative chemotherapy and had no resection. 
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ASCITIS AND LIVER METASTASES DETECTED 
 
 
Figure 13: Comparison of ascitis and liver metastases detected on CT and laparoscopy  
CT- computed tomography 
Liver mets- liver metastases 
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Computed tomography detected 6 patients with ascites and none with liver metastases. On the 
contrary laparoscopy detected 10 patients with ascites and 5 with liver surface metastases. 
 
 
CHANGE IN PLAN MADE AFTER STAGING LAPAROSCOPY  
 
Figure 14: Change in plan according to laparoscopic findings 
Based on staging laparoscopy a change in original plan was made in 46% of the study 
population. The original plan was executed in rest of the study population. This includes 
1. Laparotomy avoided 
2. Lymphadenectomy plan revised 
3. Resection plan revised (curative to palliative or palliative to curative) 
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LAPAROTOMY AVOIDED 
 
Figure 15: Laparotomy avoided 
 
Based on the staging laparoscopic findings, unnecessary laparotomy was avoided in 16.67% of 
the study population. 
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RESECTION PLAN REVISED  
 
Figure 16: Resection plan revised 
18 patients in the study had revision in original plan made for resection. The change in plan was 
from curative resection to palliative resection. This made up 33% of the study population. 
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LYMPHADENECTOMY PLAN REVISED 
 
Figure 17: Lymphadenectomy plan revised 
Lymphadenectomy plan was revised in 9 percentage of the study population in whom any form 
of resection was done. That is in these patients, the original plan was to perform a D2 
gastrectomy. However in view of the peritoneal disease found, a lesser lymphadenectomy was 
performed.  
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OPERATION PERFORMED  
 
Figure 18:Operations performed 
 
Major surgical resection was avoided in 16.67%.  44% of resectable tumors underwent total 
gastrectomy while rest had subtotal gastrectomy. 
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AGREEMENT OF CT AND LAPAROSCOPY WITH HISTOPATHOLOGY FOR T- STAGE OF THE TUMOR 
 CT LAPAROSCOPY 
k 0.194 0.342 
p 0.0133 0.0004 
Table 10: Agreement of ct and laparoscopy with histopathology for t- stage of the tumor 
 
Figure 19: Agreement of ct and laparoscopy with histopathology for t- stage of the tumor 
CT- computed tomography 
SL- staging laparoscopy 
p- P value 
k- Kappa value 
0
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k
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The kappa value for computed tomography for T- stage was 0.194. This according to the Altman 
criteria is poor agreement with gold standard. However this is not statistically significant 
because the p value above 0.05. 
The kappa value of 0.342 for staging laparoscopy for T- stage shows fair agreement with gold 
standard and this is statistically significant. 
AGREEMENT OF CT AND LAPAROSCOPIC FINDINGS WITH HISTOPATHOLOGY FOR SITE OF THE 
TUMOR 
 
Figure 20: Kappa value for computed tomography and staging laparoscopy for tumor site 
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Figure 21: P value for the site of the tumor 
 
CT- computed tomography 
 
For distal tumours, CT scan and laparoscopy are equally effective in assessing T staging. 
However, in proximal tumours, staging lap scores over CT scan. 
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PERITONEAL FLUID CYTOLOGY  
 
 
Figure 22: Peritoneal fluid cytology positivity rate 
Peritoneal fluid positive rate was 7.58% 
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HISTOPATHOLOGICAL T- STAGE 
 
 
Figure 23: Final pathological T- stage 
Majority of the tumors were T4 (51%) and it was followed by T3 disease (33%).  
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PERITONEAL DISEASE BREAK UP ACCORDING TO THE T- STAGES 
 
Figure 24: peritoneal disease according to T-stages 
Peritoneal disease was found only in T3 and T4 disease. None of the patients with T1 or T2 
disease had peritoneal disease. As expected, the majority of peritoneal disease was found in 
patients with T4 disease. 
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HISTOPATHOLOGICAL N- STAGE  
 
Figure 25: Final pathological N- stage 
Majority of the patients had N3 or N0 disease.  
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DURATION OF LAPAROSCOPY 
VARIABLE MEAN MINIMUM MAXIMUM 
LAP DURATION 20.29 10 60 
Table 11: Duration of staging laparoscopy in minutes 
The staging laparoscopy was performed just prior to the planned resectional surgery. Therefore 
this may not be an accurate representation of the actual time needed for the staging procedure 
alone.  
Maximum time taken for performing staging laparoscopy was 60 minutes. The time taken was 
more when a frozen section biopsy was performed, in select patients. The average time taken 
for the staging laparoscopy procedure in this study was 20 minutes. 
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DISCUSSION 
Carcinoma stomach remains one of the commonest causes of cancer related deaths in India. In 
the light of ever changing technology in diagnostics, newer insights into chemotherapeutic 
agents, surgical skills, there needs to be a relook at the tools we employ to stage the disease. 
We studied the use of laparoscopy as a staging tool in carcinoma stomach. It was compared 
with computed tomography.  74 patients who were diagnosed with carcinoma stomach by 
endoscopy and biopsy were analysed. All patients had computed tomography as the 
preliminary staging investigation.  Among the 74 patients, 8 who had a staging computed 
tomography at other centers were excluded from the study to bring uniformity in procedure 
and reporting of the scans. 66 patients were therefore included in the final analysis.  
DEMOGRAPHICS 
A male preponderance was seen, with 65% of the study cohort being males and 35% being 
females. The mean age of the study population was 53 years. The minimum age was 19 years 
and maximum age was 77 years.  These demographic findings are in keeping with the literature. 
(14) 
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Figure 26: Prospective study comparing CT and Staging laparoscopy findings and assessing the 
impact on treatment plan. 
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SAFETY OF THE PROCEDURE 
There is general agreement that staging laparoscopy is a safe procedure. It is well tolerated and 
the immediate complications are minimal with rate ranging from 0 to 3 percent. In this study 
patients who were deemed operable on computed tomography underwent staging 
laparoscopy. There were no major complications associated with the staging laparoscopy. (7)(9)  
CONTRIBUTION OF LAPAROSCOPY IN CHANGE OF TREATMENT PLAN  
There was a change in plan in 30 patients out of 66 patients recruited for the study. This 
constituted 46% of the study population. The original plan was executed in rest of the study 
population. Systematic review by Leake et al did show the use of staging laparoscopy altered 
treatment in 8.5%to 59.6% of cases in various studies.(43) The various changes in treatment 
plan included the following: 
1. Laparotomy avoided 
2. Lymphadenectomy revised 
3. Resection plan revised 
The most important finding of this study was that unnecessary laparotomy was avoided in 11 
patients of the 66 patients recruited for the surgery. This was 15% of the study population. A 
systematic review by Leake et al of 21 articles published between January 1998 and December 
2009 on the accuracy and indication of staging laparoscopy showed that the laparotomy was 
avoided in 8.5% to 43.8%.(43) 
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Lymphadenectomy revised was revised in 5 patients out 55 patients who underwent resection 
(9%). Similarly Resection plan was revised from either curative to palliative or palliative to 
curative in 18 patients (33%).  
 
ABILITY OF STAGING LAPAROSCOPY TO DETECT PERITONEAL DISEASE AND LIVER SURFACE 
METASTASES UNDETECTED ON COMPUTED TOMOGRAPHY 
There are many studies which show that computed tomography can miss peritoneal and 
surface liver metastases. This study showed that laparoscopy could detect peritoneal disease 
and liver surface metastases which computed tomography could not detect. Peritoneal disease 
was classified into P1, P2 and P3 – peritoneal metastases as described by Japanese 
classification.(9) Of the 66 patients included in the study computed tomography did not pick up 
any peritoneal disease while laparoscopy staging laparoscopy detected 23 patients with 
peritoneal metastases. Five of these were P1 disease, 11 were P2 disease and 7 were P3 
disease. Computed tomography detected 6 patients with ascites and none with liver 
metastases. On the contrary laparoscopy detected 10 patients with ascites and 5 with liver 
surface metastases.  
 Possik et al have shown that the sensitivity for peritoneal metastases for laparoscopy is 87% 
and for liver metastases is 87%. In a study conducted by Gretschel et al the sensitivity of 
laparoscopy for peritoneal disease was 85%. While that of computed tomography was 28%. He 
concluded that the aim of laparoscopic staging should involve detecting all patients with P3      
disease as this group does not benefit from any surgical resection and on the contrary it will 
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add on to their morbidity. Patients with numerous peritoneal deposits who undergo 
laparotomy have higher postoperative morbidity (13–23 per cent) and mortality (10–26 per 
cent).(7)(9) 
STAGING LAPAROSCOPY IN EARLY AND ADVANCED GASTRIC CANCER 
It was noted in this study that all the patients who had peritoneal disease detected on staging 
laparoscopy had either T3 or T4 disease. This is in concordance with the current literature. So a 
staging laparoscopy may be safely avoided when the disease is limited to the mucosa and 
submucosa (T1). However when the disease involves the muscularis mucosa or beyond, (T2 or 
beyond), a staging laparoscopy forms an essential part of the staging and needs to be 
performed.   
AGREEMENT OF LAPAROSCOPIC FINDINGS WITH THAT OF HISTOPATHOLOGICAL FINDINGS 
 In this study we looked at the ability of staging laparoscopy to detect the T stage of tumor. In 
55 patients who underwent resection the findings of the computed tomography and 
laparoscopy were compared with the gold standard i.e. the histopathology. Statistical measure 
used here was the kappa statistics which looks into the agreement of the two tests with gold 
standard. The kappa value for computed tomography for T- stage was 0.194. This according to 
the Altman criteria is poor agreement with gold standard and is not statistically significant (p > 
0.05). The kappa value of 0.342 for staging laparoscopy for T- stage shows fair agreement with 
gold standard and this was statistically significant.    
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When site specific agreement was looked at, both computed tomography and laparoscopy 
gives good agreement values for distal tumours. . However for the more proximal the tumors, 
laparoscopy identifies the site better than the CT scan.  These findings are in agreement with 
systematic review by Leake P A et al, where the laparoscopic findings had moderate to 
substantial agreement with the final pathological findings when kappa statistics were used. 
There have been a few Indian studies in this regard. The recent one done by Kakroo et al found 
that the laparoscopy identifies the T-Stage of the disease with diagnostic accuracy of 81% with 
a sensitivity of 76% and specificity of 90%. 
SIGNIFICANCE OF PERITONEAL FLUID POSITIVITY 
Performing laparoscopy also helped in collecting peritoneal fluid for cytology. Peritoneal fluid 
was positive in 7.58% by using the routine papanicolaou staining. Those patients with positive 
peritoneal cytology are bound to harbor micro metastases on the peritoneum. They are at a 
higher risk in developing in disseminated peritoneal carcinomatosis. According to the recent 
NCCN guideline s these patients will be considered as metastatic disease In Japan peritoneal 
washings have become mandatory and part of the staging system. They have grouped these 
patients into CY1 disease and are staged as stage IV by the Japanese Classification of Gastric 
Carcinoma. Hence the Japanese do not offer gastrectomy with a curative intent in these 
patients.(44) 
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TIMING OF LAPAROSCOPY 
In the west, laparoscopic staging is done as a standalone procedure, prior to the gastric 
resection. However in this study, the staging laparoscopy was done just prior to the resectional 
operation, in the same sitting. This was planned, so as to overcome the logistic constraints of 
operating time availability and also to avoid the additional financial constraints to the patient.  
Our study shows that the staging laparoscopy can be effectively performed during the same 
sitting as the resectional operation and therefore avoiding the need for the second anesthetic 
procedure. 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
1. Laparoscopic staging adds additional staging information in the staging of carcinoma 
stomach. 
2. Peritoneal disease and liver surface metastases are better detected by laparoscopy than 
computed tomography. The detection of these can avoid unwarranted resectional 
surgery. 
3. The detection of T4 disease was better by staging laparoscopy, when compared to CT 
scan. 
4. Laparoscopy was better than the CT scan in assessing the proximally located tumors of 
the stomach. 
5. Peritoneal fluid cytology has a low detection rate when Papanicolaou stain is used. It did 
not add value to the laparoscopic staging due to its proximity to the resection.  
6. Staging laparoscopy may be effectively performed in the same sitting as the primary 
operation, thereby avoiding the need for an additional procedure under general 
anesthesia. 
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ANNEXURE 
1 
 
CLINICAL RESEARCH FORM 
Staging Laparoscopy in Carcinoma Stomach  
 
PATIENT NAME    
Hospital No.  Address  
Age   
Sex   
Email ID   
Telephone   
 
P 
Initial investigation leading to diagnosis:       endoscopy / barium meal / other 
Date of diagnosis: 
 
Barium meal: Y / N 
 
Date: _____________ 
 
Findings: 
Endoscopy: Y / N 
Date: _____________ 
Site of ulcer / tumour: 
     GOJ 
     Fundus:  GC / LC 
     Body:      GC / LC 
     Antrum:   GC / LC 
 
Histology: 
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CT chest / Abdomen: Y/N 
Date: _____________ 
 
Site of tumour: 
Thickening of stomach: P / A 
Loco regional spread:   P / A 
Ascites:                         P / A 
Nodes:                          P / A 
Liver mets:                    P / A 
Lung mets:                    P / A 
Peritoneal mets             P/A 
   
PET Scan: Y/N 
Date: _____________ 
Metastasis:  Y/N 
Location of mets: 
Endoscopic US: Y/N 
Date: _____________ 
Staging:T 
              N 
FNA node done: Y/N 
 
Pre op staging: 
 
T____N____M____ 
MDTM 
Date: _____________ 
Plan: 
                                                   
                                         PART – B – Surgical 
 
Date of surgery: 
Staging laparoscopy: Y/N 
Findings: 
Loco regional spread:   P / A 
Ascites:                         P / A 
Nodes:                          P / A 
Liver mets:                    P / A 
Peritoneal mets             P/A       P1/ P2/P3 
Cytology:  +ve / -ve 
Biopsies taken : Sites   
        
                             Number 
Surgery done: 
 
Palliative / Curative: 
Type of resection (SURG) – R0 / R1 / R2 
Change in Plan  
No change 
Laparotomy  avoided 
85 
 
Decision to attempt curative resection revised 
Decision on lympadenectomy revised (D2 to D1,D1toD2) 
Neoadjuant therapy 
 
If palliative, Why?   -   Residual primary tumour 
 
                                      Residual nodes   
                                      Peritoneal disease 
 
                                      Liver mets 
 
 
Histology: 
 
Tumour site: C / F / B / A 
 
Tumour type: 
 
Tumour differentiation:   Well diff 
                                        Moderately 
                                        Poorly 
 
T: Tis / T1 / T2 / T3 / T4. 
 
N:Nx / N0 / N1 / N2 / N3. 
 
Proximal margin – involved / free of 
tumour 
 
Distal margin: involved / free of tumour 
 
Based on histology 
 
     Curative resection   R0 
     Palliative resection  R1 
                                      R2 
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ANNEXURE 2 
INFORMED CONSENT FORM 
Study title: Laparoscopic staging of carcinoma of stomach and its impact on treatment plan. 
Study Number: 
Subject’s Initial: 
Date of Birth/ Age: 
i. I confirm that I have read and understood the information sheet for the above mentioned study and have 
had the opportunity to ask questions to the investigator. 
ii. I understand that my participation in the study is voluntary and that I am free to withdraw from the study 
at any point of time without giving any reason, without my medical care or legal rights being affected.  
iii. I understand that my permission will not be required to look at my health records both in respect f the 
current study and any other further research that may be conducted in relation to it even if I withdraw 
from the study. I agree to this access. However I understand that my identity will not be revealed in any 
information released to third parties or published. 
iv. I understand that my involvement in the study will include performing diagnostic Laparoscopy on me. The 
risks involved include 1) Bleeding0.3% 2)Wound site Infection 1.2% 3)Bowel injuries 0.2% 
v.  I understand that ascetic fluid cytology will be done and biopsies from suspicious lesions will be taken. 
vi. I understand that photographic and or video graphic documentation of intraoperative findings will be 
done. 
Herewith I give fully informed consent for the study. 
Signature or thumb impression of the subject/legally acceptable representative 
-------------------------------------------------------------- 
Date: 
Place: 
Signatory’s Name: 
Signature of the investigator: ------------------------ 
Date: 
Investigator’s Name  : 
Signature of the witness:------------------------------- 
Date: 
Name of the witness: 
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ANNEXURE 3 
 
CT ABDOMEN AND PELVIS  REPORTING FORMAT 
 
Findings: 
STOMACH  : 
Location and T staging of the mass 
Loco-regional spread 
See staging below 
LIVER - comment on metastatic lesion 
SPLEEN - 
GB - 
PANCREAS - 
ADRENALS - 
KIDNEYS - 
BOWEL, MESENTERY, OMENTUM - 
LYMPHADENOPATHY: 
Mention nodal spread 
--Perigastric 
---Extra perigastric 
a)  greater  omental  - 
b)  lesser  omental  - 
c)  mesenteric  - 
d)  diaphragmatic  - 
e)  para-aortic  - 
f)  para-iliac  - 
FLUID -Present / absent 
BLADDER: 
PROSTATE /UTERUS: 
SEMINAL VESICLES/OVARIES 
INGUINAL ORIFICES - 
ABDOMINAL WALL - 
BLOOD VESSELS - 
VISUALISED LUNG BASES - 
VISUALISED BONES - 
IMPRESSION: 
year old male / female with suspected 
carcinoma stomach, CECT abdomen 
shows: 
Comment on: 
1. Location 
2. T staging 
3. Loco regional spread 
4. Nodal disease 
5. Free fluid   
6. Liver and peritoneal metastasis  
 
-
Office of the Addl. Vice Principal (Research) Christian Medical College,
Vellore 632 002
Ref: Res/09/20 11 December 13,2011
Dr. Ashish Sam Samuel
PG Registrar
Department of Surgery
Christian Medical College
Vellore 632 002
Dear Dr. Samuel,
Sub: FLUID Research grant project NEW PROPOSAL:
Laparoscopic staging in carcinoma of the stomach and its impact on treatment
plan
Dr. Ashish Sam Samuel, PG Registrar, Surgery, Dr. Inian Samarasam, Dr. Sam
Varghese, General Surgery, Dr. Anu Eapen , Radiology, Dr. Anna Pulimood,
Pathology, Dr. Dipti Masih, Pathology.
Ref: IRB Min. No. 7622 dated 3.10.2011
I enclose the following documents:-
1. Institutional Review Board approval
2. Agreement
Could you please sign the agreement and send it to Dr. Gagandeep Kang, Addl. Vice
Principal (Research), so that the grant money can be released?
With best wishes,
Yours sincerely,
~
Dr. Alfred Job Daniel
Principal & Chairperson (Research Committee)
Institutional Review Board
/
HOSPITAL NAGE SEX
GOJ
GC LC GC LC GC
447251F 47 M 0 0 0 0 0 1
440326F 63 M 0 0 0 0 1 1
385327F 49 M 1 0 0 0 0 0
721760C 64 M 1 0 0 1 1 1
371381F 45 M 1 0 0 0 0 0
077339D 60 M 0 0 0 0 0 1
071079F 62 M 0 0 0 0 0 1
098268F 45 M 0 0 0 0 1 0
919007D 24 F 0 0 0 0 0 0
072749F 37 F 0 0 0 0 0 1
049610F 44 F 0 0 0 0 0 1
071969F 56 M 0 0 0 0 1 0
131407F 46 M 0 0 0 1 1 0
111674F 50 F 1 1 0 1 0 0
080872F 71 F 0 0 0 1 1 1
348642F 58 M 0 0 0 0 0 1
259252F 56 M 1 0 0 0 1 0
259614F 58 M 0 0 0 0 1 0
265536F 77 M 1 0 0 1 0 0
268714D 56 M 0 0 0 1 1 0
274177F 40 F 0 0 0 0 1 0
ANTRBODYFUNDUS
ENDOSCOPY
SITE
THICKENIN LOCOREGIOASCITES NODES
GOJ FUNDUS BODY ANTRUM
LC
1 0 0 0 1 1 0 0 0
1 0 0 0 1 1 0 1 1
0 1 0 0 0 1 0 0 0
1 0 0 1 1 1 0 0 0
0 1 1 0 0 1 0 0 1
1 0 0 0 1 1 1 1 1
1 0 0 0 1 1 0 0 1
0 0 0 1 0 1 1 0 1
0 0 0 1 0 1 0 0 1
1 0 0 0 1 1 0 0 1
1 0 0 1 1 1 0 0 0
0 0 0 0 1 1 0 0 0
0 0 0 1 0 1 0 0 1
0 0 0 1 0 1 0 0 0
1 0 1 1 0 1 0 0 0
1 0 0 0 1 1 0 0 0
1 0 0 0 1 1 1 0 1
1 0 0 0 0 0 0 0 0
0 0 0 1 0 1 0 0 0
0 0 0 1 1 1 0 0 0
0 0 0 1 0 1 0 0 0
RUM
SITE
CT
LIVER METSLUNGMETSPERITONEA
TIS T1 T2 T3 T4 N0
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 1 0
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 0
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 0 1 1
0 0 0 0 0 0 1 0 0
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 1 0 1
0 0 0 0 0 1 0 0 1
T
PREOP STAGIN
N1 N2 N3 M0 M1 GOJ FUNDUS BODY ANTRUM
0 0 0 1 0 0 0 0 1
1 0 0 0 1 0 0 1 1
0 0 0 1 0 1 0 0 0
1 0 0 0 1 0 0 1 0
0 0 0 0 1 1 1 0 0
0 0 0 0 1 0 0 0 1
0 0 0 1 0 0 0 0 1
0 0 0 1 0 0 0 1 0
1 0 0 1 0 1 1 1 0
0 0 0 0 1 0 0 0 1
0 0 0 1 0 0 0 0 1
0 0 0 1 0 0 0 0 1
0 0 0 0 1 0 0 1 0
0 0 0 1 0 0 0 0 0
0 0 0 1 0 0 0 0 0
0 0 0 1 0 0 0 0 1
0 0 0 1 0 0 0 1 1
0 0 0 1 0 0 0 0 0
0 0 0 1 0 0 0 1 0
0 0 0 0 1 0 0 0 0
0 0 0 1 0 0 0 0 0
N M SITE
 NG  
LOCOREGIOASCITES NODES LIVER METS
T3 T4 P1 P2 P3
1 0 0 0 0 0 0 0 0
0 1 1 1 0 0 0 0 1
0 1 0 1 0 0 0 0 0
0 1 1 1 0 0 0 0 1
0 1 1 0 0 0 0 0 1
0 1 1 1 0 0 0 1 0
1 0 0 0 0 0 0 0 0
0 1 1 0 0 1 0 0 0
0 1 0 0 0 0 0 1 0
0 1 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
1 0 0 0 1 0 0 0 0
0 1 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0
0 1 0 1 1 1 0 1 0
0 0 1 0 0 0 0 0 0
STAGE PERITONEAL
STAGING LAP
SURGERY DONE PALLIATIVECURATIVE
BIOPSIES TG ST NO RESECTION R0
POSITIVE NEGATIVE
0 0 0 0 1 0 0 1 1
0 1 0 0 0 1 1 0 0
0 1 0 1 0 0 0 1 1
1 0 0 0 0 1 1 0 0
0 0 0 0 0 1 1 0 0
0 0 0 0 1 0 1 0 0
0 1 0 0 1 0 0 1 0
0 0 0 0 1 0 0 0 0
0 0 0 1 0 0 1 0 0
0 1 1 0 1 0 1 0 0
0 1 0 0 1 0 1 0 0
0 1 0 1 0 0 0 1 1
0 1 1 0 0 1 0 0 0
0 1 0 1 0 0 0 1 1
0 1 0 0 1 0 0 1 1
0 1 0 0 1 0 0 1 1
0 0 0 1 0 0 0 1 1
0 1 0 1 0 0 0 1 1
0 1 0 1 0 0 0 1 1
0 1 0 0 0 1 1 0 0
0 1 0 1 0 0 0 1 1
CYTOLOGY
 
ANGE IN PLAN
R1 R2 NIL LAPAROTO  RESECTION  LYMPH ADE  NT RESIDUAL PRESIDUAL N
0 0 1 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0
0 0 0 0 1 0 0 0 0
0 1 0 0 1 0 0 0 0
1 0 1 0 0 0 0 0 0
0 1 1 0 0 0 0 0 0
0 1 0 0 1 0 0 1 1
0 1 0 0 1 0 0 0 0
0 1 0 0 0 1 0 0 1
0 0 0 0 1 0 0 0 0
0 0 0 0 0 0 1 0 0
0 0 1 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0
0 0 0 1 0 0 0 0 0
0 0 1 0 0 0 0 0 0
RESECTION PALLIAT  
PERITONEA  LIVER METS
GOJ FUNDUS BODY ANTRUM ADENO SQ WELL
0 0 0 0 0 1 0 0 0
0 0 0 0 0 0 0 0 0
0 0 1 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
1 0 0 0 1 1 1 0 0
0 0 0 0 0 1 1 0 0
0 1 0 0 1 0 1 0 0
1 0 0 0 1 1 1 0 0
1 0 0 0 0 1 1 0 0
0 0 0 0 0 1 1 0 0
0 0 0 0 0 1 1 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 1 0 0 0 0
0 0 0 0 1 1 1 0 0
0 0 0 0 0 1 1 0 0
0 0 0 0 0 1 1 0 0
0 0 0 0 1 0 1 0 0
0 0 0 0 1 0 1 0 0
1 1 0 0 0 0 0 0 0
0 0 0 0 1 0 1 0 0
TUMOR TYPE
TIVE FOR
DIFSITE
T STAGE
MOD POORLY TIS T1 T2 T3 T4 N0 N1
0 1 0 0 0 1 0 0 0
0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 1 0 1
0 1 0 0 0 1 0 1 0
0 1 0 0 0 0 1 0 1
1 0 0 0 0 0 1 0 0
0 1 0 0 0 0 1 0 1
1 0 0 0 0 1 0 0 1
0 1 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 1 1 0
0 1 0 0 0 1 0 1 0
0 1 0 0 0 0 1 0 0
0 0 0 0 0 1 0 0 0
1 0 0 0 1 0 0 0 0
0 0 0 0 0 0 0 0 0
1 0 0 1 0 0 0 1 0
HPE
FERENTIATION N STAGE
CURATIVE
PROXIMALMDISTAL MA R0 R1 R2 LAP DURATION
N2 N3
1 0 0 0 1 0 0 15
0 0 0 0 0 0 0
0 1 0 0 1 0 0 30
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 1
0 0 0 0 1 0 0
0 0 1 0 0 1 0
0 1 0 0 1 0 0
0 0 1 1 0 0 1
0 0 1 0 0 0 1
0 1 0 0 1 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0 15
0 0 0 0 1 0 0
0 0 0 0 1 0 0
0 1 0 0 1 0 0 15
1 0 0 0 0 0 0 15
1 0 0 0 1 0 0 10
0 0 0 0 0 0 0
0 0 0 0 1 0 0 40
 
PALLIATIVE
